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Primary infection of healthy individuals with human cytomegalovirus (HCMV) is normally
asymptomatic but results in the establishment of a lifelong infection of the host. One
important cellular reservoir of HCMV latency is the CD34+ haematopoietic progenitor
cells resident in the bone marrow. Viral gene expression is highly restricted in these cells
with an absence of viral progeny production. However, cellular differentiation into mature
myeloid cells is concomitant with the induction of a full lytic transcription program, DNA
replication and, ultimately, the production of infectious viral progeny. Such reactivation of
HCMV is a major cause of morbidity and mortality in a number of immune-suppressed
patient populations. Our current understanding of HCMV carriage and reactivation is that
cellular differentiation of the CD34+ progenitor cells through the myeloid lineage, resulting
in terminal differentiation to either a macrophage or dendritic cell (DC) phenotype, is crucial
for the reactivation event. In this mini-review, we focus on the interaction of HCMV with
DCs, with a particular emphasis on their role in reactivation, and discuss how the critical
regulation of viralmajor immediate-early gene expression appears to be delicately entwined
with the activation of cellular pathways in differentiating DCs. Furthermore, we also explore
the possible immune consequences associated with reactivation in a professional antigen
presenting cell and potential countermeasures HCMV employs to abrogate these.
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INTRODUCTION
Human cytomegalovirus (HCMV) remains a major cause of
pathology in a number of patient populations. Pathogenesis cor-
relates with an impaired immune response such that disease is
particularly associated with congenital infection in utero or dur-
ing infection and reactivation in immune-suppressed transplant
patients as well as in immune-compromised, late-stage AIDS
patients (Pass et al., 1983; Revello and Gerna, 2004; Legendre
and Pascual, 2008). However, while an absence of a cellular
immune response is a key factor, it has also been suggested
that HCMV may also represent a clinical problem to critically
ill non-immune-compromised individuals. For instance, in inten-
sive care units, HCMV can present as a secondary complication –
with the reactivation of latent HCMV representing the major
source of infection (Papazian et al., 1996; Limaye et al., 2008; Kalil
and Florescu, 2009). Pertinently, despite a number of strategies
to control HCMV infection, the virus remains a major health
burden.
The ability of HCMV to establish a latent infection likely con-
tributes to the sero-prevalence within the healthy population.
Furthermore, much of the well-documented, virus-associated
pathogenesis in clinical settings results from reactivation of latent
virus reservoirs. As such, understanding the underlying princi-
ples that govern HCMV latency and reactivation is important
for deciphering the pathobiology of HCMV. In this review, we
explore the intimate relationship between HCMV and myeloid
dendritic cells (DCs). DCs, key antigen presenting cells (APCs),
are both sites of reactivation from latency as well as primary lytic
infection and thus have a central role in the lifecycle of HCMV.
Indeed, the abundance of immune evasion molecules expressed by
HCMV is testament of a close relationship with a pivotal cell type
that orchestrates innate and adaptive immune response following
infection.
HCMV LATENCY AND THE MYELOID LINEAGE
It is now well established that HCMV can persist latently in
haematopoietic progenitor cells resident in the bone marrow
(Mendelson et al., 1996; Sindre et al., 1996; Zhuravskaya et al.,
1997; Hahn et al., 1998). Despite the potential ability of these pro-
genitor cells to give rise to bothmyeloid and lymphoid lineages, the
detection of HCMV DNA in peripheral blood of naturally latent
carriers is restricted to the myeloid lineage (Bevan et al., 1991;
Taylor-Wiedeman et al., 1991, 1993). In such healthy individu-
als, this carriage of virus DNA in peripheral blood monocytes,
but not T or B cells, is independent of infectious virus produc-
tion (Taylor-Wiedeman et al., 1991, 1994). These observations
are consistent with a lack of detectable infectious virus in the
blood of healthy donors as well as early clinical observations which
showed that HCMV transmission in blood transfusions was sig-
niﬁcantly diminished by prior leukocyte depletion (Gilbert et al.,
1989). However, the reactivation of HCMV, in vitro, can be trig-
gered from these early myeloid cells (CD34+ and CD14+ cells)
by differentiation (Reeves and Sinclair, 2008). Some early studies
showed that treatment of monocytes with mixtures of cytokines
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that promote macrophage differentiation could trigger the reac-
tivation of immediate-early gene expression (Taylor-Wiedeman
et al., 1994) and, in some instances, infectious virus (Soderberg-
Naucler et al., 1997). Subsequent studies have now established
that HCMV reactivation occurs in myeloid progenitors differenti-
ated to DCs by speciﬁc cytokine stimulation (Reeves et al., 2005b;
Reeves and Compton, 2011). Indeed, the ﬁrst report detailing
the reactivation of infectious virus from peripheral blood com-
partment cells of healthy seropositives required the allogeneic
stimulation of monocytes (Soderberg-Naucler et al., 1997). The
“cytokine storm,” associated with the allogeneic T-cell reaction,
likely triggered virus reactivation and suggested a contribution
of pro-inﬂammatory cytokines which, however, remained unde-
ﬁned (Soderberg-Naucler et al., 1997, 2001). Nevertheless, an
interesting aspect of these studies was the phenotype of the dif-
ferentiated monocyte: The cells reactivating HCMV co-expressed
both macrophage (CD68) and, interestingly, DC markers (CD83).
Parallel studies from the Mocarski laboratory, using a Gran-
ulocyte/macrophage – progenitor (GM-P) model, showed that
reactivation of HCMV was concomitant with DC lineage com-
mitment (based on CD1a expression) suggesting that DCs, as
well as macrophages, were important sites of HCMV reactiva-
tion in vivo (Hahn et al., 1998). Subsequently, our own work has
now shown that differentiation, ex vivo, of both CD34+ and
CD14+ cells to speciﬁc DC phenotypes is important for reacti-
vation (Reeves et al., 2005b; Reeves and Compton, 2011; Huang
et al., 2012). Importantly, isolated circulating unstimulated DCs
from the peripheral blood of healthyHCMVcarriers show low lev-
els of expression of viral immediate-early RNA consistent with the
inductionof reactivationof HCMVinDCs in vivo (Reeves andSin-
clair, 2013). Our current understanding regarding the myeloid cell
differentiation and the role of in vitro differentiation and cytokine
signaling based on studies onnaturally latentHCMV is reviewed in
Figure 1.
DEFINING THE DENDRITIC CELL LINEAGE
Beginning in the 1970s, the late Ralph Steinman and colleagues
identiﬁed and characterized, in a series of studies, a new pop-
ulation of cells with stellate (or dendritic) morphology. These
were distinct from other cell types based on a prodigious ability
to activate T-cell responses and a biochemical signature that was
distinct from that of macrophages (Steinman and Cohn, 1973,
FIGURE 1 | Natural latency in myeloid progenitors and their DC
derivatives.The natural differentiation of HCMV from bone marrow
progenitors (CD34+) via granulocyte-macrophage progenitors (GMPs)
through to circulating CD14+ monocytes and blood DCs in the peripheral
blood is illustrated (Grey box). Latency is maintained in pre-DC populations
exempliﬁed by a lack of major IE transcription and no infectious virus
production. A number of transcripts have been detected in these different
cellular populations ( = detected; X = failure to detect; ND = No Data) and
have been suggested to represent putative latent transcripts. Upper
transcripts CLTs to LUNA have been veriﬁed in multiple laboratories whereas
lower transcripts await independent veriﬁcation. The in vitro differentiation of
myeloid progenitors to DC cell types that support HCMV reactivation is
shown with the key cytokines implicated in reactivation illustrated from these
studies of naturally latent myeloid cells.
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1974; Steinman et al., 1974). Until then, it was generally believed
that macrophages were the major orchestrators of the adaptive
immune response and, indeed for some time after the initial
identiﬁcation of DCs, this view persisted. However, in a series
of elegant experiments Steinman et al. (1983) identiﬁed a unique
cell population that, although representing less than 1% of the
total cells in the spleen, was a major regulator of the immune
response (Steinman and Witmer, 1978) and was clearly important
for controlling self and non-self recognition – thus illustrating
the existence of a cell type that had been postulated by Erhlich
some 40 years earlier. Subsequently, it was shown that these
cells were resident in a number of tissues known to be at the
interface of host pathogen responses as well as highly enriched
in lymph nodes of individuals following exposure to pathogens
and were eventually termed classical or conventional DCs (cDCs)
in order to differentiate them from the subsequently discov-
ered plasmacytoid DCs (reviewed in Banchereau et al., 2000;
Merad et al., 2013).
A key aspect in deﬁning the phenotype of DCs is determining
their differences from macrophages. Both cell types can arise from
monocyte precursors and often share anatomical location. The
“text book” view is that macrophages are highly phagocytic and
are key players in the innate response, whereas DCs interface with
the adaptive response via endocytosis and subsequent process-
ing and presentation of antigens. However, CD11c− macrophages
have been shown to activate T-cell responses (Pozzi et al., 2005).
Conversely, the well-described, macrophage-induced tissue dam-
age via the induction of cell death pathways, has been suggested
for DCs also (Serbina et al., 2003; Stary et al., 2007). Currently,
differentiation of the two cell types has largely been based on
roles in the innate and adaptive immune response and the expres-
sion of cell surface markers. Again, however, the expression of
CD68 – a classical macrophage marker – has been detected on
myeloid DCs (DC-SIGN-positive cells) resident in human kid-
ney (Segerer et al., 2008). It is interesting to note that CD68 was
also detected concomitantly with CD83 on allogenically stim-
ulated monocyte reactivating HCMV (Soderberg-Naucler et al.,
1997) suggesting the presence of a heterogeneous phenotype
under certain conditions. Given these caveats, it is perhaps
not unsurprising that the macrophage/DC system shows a high
degree of plasticity between the cell types and may be bet-
ter regarded as a spectrum of different cell type (Hume et al.,
2002). This plasticity would be consistent with both these cell
types being members of a larger mononuclear family which share
a degree of overlapping functions and ontogeny (Hume et al.,
2002).
Despite these caveats, a number of studies have gone on to
show that the original cDCs indentiﬁed by Steinman and Cohn
(1973) represented a unique cell type with distinct biochemical
and immunological properties. The DC, existing in an imma-
ture state in peripheral blood truly represented the sentinel of the
immune response (Banchereau and Steinman, 1998). Since then,
the study of DCs has increased exponentially as researchers seek
to understand the interaction of DCs with other immune cells
in both infection and auto-immunity, as well as trying to har-
ness these cells as potential therapeutic agents against a number
of infectious and non-infectious diseases. The very low frequency
of DCs in peripheral blood has led investigators to study methods
to generate DCs in vitro from, predominantly, myeloid precursors
and this has driven a substantial expansion of the investigation
of these unique cells (Sallusto and Lanzavecchia, 1994; Caux et al.,
1997; Strobl et al., 1997a,b). Importantly, a number of functions of
these in vitro derivedDCs have beenmapped onto their putative in
vivo counterparts, basedon similar expressionof cell surfacemark-
ers, as well as, more recently, by transcriptional proﬁling (Merad
et al., 2013). Furthermore, augmentation with murine studies has
begun to lead to a consensus on their functions with a concomitant
discord on the ontogeny of the different DC populations, which is
discussed below (Geissmann et al., 2010; Schulz et al., 2012; Merad
et al., 2013).
CLASSICAL DCs
Classical DCs are characterized by an incredibly short half-life
(3–5 days) and are replenished from bone marrow precursors
in Flt-3L-dependent manner (Liu et al., 2007; Waskow et al.,
2008). In general, immature cDCs are highly endocytic and
detect pathogens in the periphery. Upon detection of a pathogen,
and thus antigen encounter, cDCs efﬁciently capture, process,
and present antigens in the context of MHC molecules (Merad
et al., 2013). This maturation is marked by a concomitant up-
regulation of a number of T-cell co-stimulatory molecules and
migration to lymphoid tissue and, ultimately, presentation of
antigen to T cells. This whole process, referred to as the “Langer-
hans paradigm,” provides the basis of DC activity and function
(Banchereau et al., 2000; Merad et al., 2013). Much of our under-
standing of cDCs comes from studies of the murine system.
In the simplest terms, cDCs are divided into two subsets of
cells that have differing capacities to present endogenous and
exogenous antigens. In the murine system, CD103/CD8a DCs
are characterized by the efﬁcient cross-presentation of exoge-
nous antigens via MHC class I to CD8 T cells (Belz et al., 2005;
Lundie et al., 2008). In contrast, the CD11b/CD4 cDC subset
is a comparatively poor cross-presenter and, instead, is mainly
responsible for MHC class II restricted presentation (Dudziak
et al., 2007). Mapping these functions onto human counterparts,
which is really the key aspect of such studies, has suggested
that the CD141 myeloid DC subset are similarly capable of
cross-presentation, whereas the CD1c myeloid subset in humans
bears the functional hallmarks of the CD11b population of
murine DCs (Robbins et al., 2008; Bachem et al., 2010; Crozat
et al., 2010). Indeed, it is these human populations of myeloid
DCs (the CD1c and CD141 populations) that expressed HCMV
immediate-early transcripts ex vivowhen isolated from the periph-
eral blood of healthy seropositive individuals (Reeves and Sinclair,
2013).
MONOCYTES AND MONOCYTE-DERIVED DCs (MODCs)
Monocytes are key effectors in the immune system retaining the
capacity to differentiate into both macrophage and DCs. Again
studies in the murine system have suggested the presence of two
types of monocytic cell – inﬂammatory and patrolling mono-
cytes (Geissmann et al., 2008). Although functions have not been
directly mapped to human counterparts, it is hypothesized that,
in humans, the CD14 low/CD16+ and the CD14 high populations
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represent the patrolling and inﬂammatory populations identi-
ﬁed in mice, respectively (Geissmann et al., 2008). Indeed, recent
work in the murine CMV (MCMV) model has postulated that
patrolling monocytes are an important vehicle for CMV dissem-
ination – potentially due to their immune-privileged phenotype
upon differentiation (Daley-Bauer et al., 2014). Furthermore, it
was also hypothesized that these patrolling monocytes may be
an important site of MCMV latency but this was not formally
addressed in that study. Furthermore, it was in contrast to a pre-
vious study that suggested MCMV latency was established in the
lung independent of patrolling monocyte function (Marquardt
et al., 2011). These differences aside (likely due to differences
in experimental procedure, virus strain or route of inoculation
for example), a direct analysis of CD16+ and CD16− mono-
cyte populations for the carriage of HCMV genomes in healthy
individuals would be extremely informative and could provide
pointers to help deﬁne the exact population of myeloid cells that
carry latent HCMV in vivo, which is far from clear. For instance,
latency in a sub-population of peripheral monocytes may explain
the relatively low frequency of genome-positive cells in healthy
individuals (Slobedman and Mocarski, 1999). However, that said,
studies from a number of groups have postulated that, at least
for mice, patrolling monocytes are derived from inﬂammatory
monocyte precursors (Sunderkötter et al., 2004; Varol et al., 2007;
Yona et al., 2013). If this linear route of lineage commitment under
steady-state conditions was also the same in humans, it might be
predicted that both types of monocytes may be sites of HCMV
latency. Nevertheless, very different outcomes of HCMV reacti-
vation could still occur in these different monocyte lineages. For
instance, it may be possible that both patrolling and inﬂammatory
monocytes carry latent HCMV but, in normal healthy individ-
uals, reactivation in DCs derived from inﬂammatory monocytes
may be effectively controlled by the immune system and, in con-
trast, the immune-privileged nature of patrolling monocytes may
make these cells important for persistence and transmission. In
immune-suppressed individuals, whilst a similar pattern of reacti-
vation may be seen in the absence of a controlling T-cell response,
the differentiating inﬂammatory monocytes would be less likely
to be eliminated and may be the source of disease seen in these
individuals.
Many studies of the interaction of HCMV with DCs have relied
extensively on the generation of DCs from CD14+ (thus predom-
inantly inﬂammatory monocytes). In a landmark paper, Sallusto
and Lanzavecchia (1994) described the generation of DCs from
monocytes using interleukin-4 and granulocyte/macrophage-
colony stimulating factor (GM-CSF) stimulation which bore
many similarities with studies by the Steinman group to derive
DCs in vitro from peripheral blood progenitors (Romani et al.,
1994). This protocol has become the accepted way to generate
such MoDCs in vitro and results in the generation of highly
immune reactive terminally differentiated myeloid DCs and pro-
vided strong in vitro evidence that monocytes were a precursor
of DCs. Although no deﬁnitive mapping onto in vivo DCs
has been achieved thus far, phenotyping studies suggest that
MoDCs exhibit an interstitial/dermal DC phenotype rather than a
Langerhans (see below) phenotype (Grassi et al., 1998; Duper-
rier et al., 2000). What is clear is that these in-vitro-generated
DCs are potent stimulators of a naive T-cell response and have
been used extensively to understand host/pathogen interactions
in vitro.
However, despite these in vitro observations, the contribution
monocytes made to the DC pool in vivo were far from clear. After
all, mainly based on studies performed in mice, it was accepted
that there was a circulating DC precursor that appeared indepen-
dently in the blood (Liu et al., 2009). However, these studies in
vitro argued that monocytes should be DC progenitors in vivo
and, ultimately, it was shown that microbial stimulation of mono-
cytes inmice promoted the recruitment of DC-SIGN-positiveDCs
(a marker of MoDCs) to lymph nodes and were distinct from
other DC subsets present (Cheong et al., 2010). Indeed, a chal-
lenge with a high dose of lipopolysaccharide (LPS) triggered a
profound mobilization of the monocyte pool to an effector DC
phenotype (Cheong et al., 2010). This response was rapid and
strongly supported the hypothesis that monocytes were important
for generating DCs in vivo.
LANGERHANS DCs
LangerhansDCs (LDCs)were ﬁrst described by theGermanphysi-
cian Paul Langerhans in 1868 who believed them to be neuronal
in origin due to their dendrite-like projections. These cells are
resident in the epidermis in an immature state and represent an
important ﬁrst-line response to a number of pathogens as well
as a potentially important cell type in Graft versus Host Dis-
ease (GvHD) and transplant rejection (Merad et al., 2004, 2008),
although this view is still debated (Li et al., 2010). They represent
an extremely long-lived population of cells that have the capacity
for self-renewal in the periphery (Czernielewski and Demarchez,
1987). They can be generated in vitro from both CD34+ and
CD14+ precursors and are characterized by the expression of Bir-
beck granules, Langerin, and E-Cadherin (Strobl et al., 1997a;
Geissmann et al., 1998). The cytokine TGF-b appears impor-
tant for the generation of LDCs in vitro and in vivo (Borkowski
et al., 1996; Strobl et al., 1997b) although it is becoming increas-
ingly clear they have a contentious ontogeny (Merad et al., 2002;
Ginhoux et al., 2006; Chorro and Geissmann, 2010; Schulz et al.,
2012). Although they can be generated in vitro from myeloid pre-
cursors, whether this is the case in vivo clearly remains a point
of debate. Studies in murine models have suggested that LDCs
are seeded predominantly from the yolk sac (Schulz et al., 2012)
during very early embryogenesis and that the adult LDCs are sub-
sequently replenished by the localized pool of immature LDCs
in the periphery rather than a myeloid progenitor cell (Merad
et al., 2002). Furthermore, the precise contribution of the yolk sac
to the Langerhans cells resident in adult tissue is also debated –
while the yolk sac clearly contributes to the LDC pool in the
periphery it has been postulated that second wave of LDCs are
seeded primary in later developmental stages from fetal liver
monocytes (Hoeffel et al., 2012). Consistent with monocytes hav-
ing the potential to seed LDCs, studies have shown that LCs
can be re-populated from circulating monocytes in the periph-
eral blood (Ginhoux et al., 2006) and thus the precise ontogeny
of the LDC lineage is still debated. From these many studies,
it is becoming clear that, as techniques for separating cell pop-
ulations become more sensitive, an ever increasing number of
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subsets of peripheral DCs are becoming discernible and their
differences may be due, in part, to the criteria different investi-
gators are using to deﬁne them. Furthermore, caution may also
be required when translating studies in the murine model directly
onto the human system (Mestas and Hughes, 2004; Seok et al.,
2013).
However, the concept of LDCs exhibiting longevity in the
periphery may be important in the context of HCMV biology.
Studies have shown that, in vitro, immature LDCs are not per-
missive for lytic infection and thus, potentially, HCMV could
establish a latent infection in these cells. As such, whether there is
a pool of LDCs resident in the periphery which is HCMV genome
positive is an important question. Furthermore, if circulating
monocytes can re-populate this LDC pool in the periphery in
response to inﬂammation (Ginhoux et al., 2006), this, again, could
lend itself to the establishment of a site of HCMV latency in the
periphery.
PLASMACYTOID DCs
Plasmacytoid DCs (pDCs) represent a distinct lineage considered
to be of lymphoid origin (Reizis et al., 2011). A key feature of
pDCs is the ability to secrete large quantities of type 1 interferons
in response to pathogens and, morphologically, they show little
resemblance to their myeloid counterparts, exhibiting a spheri-
cal morphology consistent with their lymphoid origin (Grouard
et al., 1997; Cella et al., 1999). Indeed, they also share little com-
monalities with cDCs. In general, they are not phagocytic and, as
such, represent poorpresenters of exogenous antigen (Gehrie et al.,
2010) – although, interestingly, their generation is also dependent
on Flt-3L (Maraskovsky et al., 2000). Consistent with their dis-
similarity to classical myeloid DCs, there is no evidence to suggest
they are important sites of HCMV latency and reactivation and,
indeed, are non-permissive for HCMV lytic infection (Kvale et al.,
2006).
IN VITRO GENERATION OF MYELOID DC SUBTYPES
DCs in vivo are constantly re-populated from the haematopoietic
stem cell compartment with fate-mapping studies suggesting that
the majority of DCs, including pDCs of lymphoid origin, arise
from the common myeloid progenitor (CMP, Manz et al., 2001).
The macrophage-DC progenitor (MDCP) that arises from the
CMP is the source of pDCs, cDCs, monocytes, and macrophages
but, interestingly in the context of HCMV biology, not the granu-
locyte or other myeloid populations (Auffray et al., 2009). Further
progenitor cell types, including the common DC progenitor, have
been identiﬁed in mice and it is likely these observations map onto
human haematopoiesis. As such, the generation of terminally dif-
ferentiated myeloid cell types from multiple progenitors has been
demonstrated.
In the context of the analysis of HCMV biology, two cell
types – the CD34+ progenitors and CD14+ monocytes – have
been used extensively. As discussed above, CD14+ monocytes can
be differentiated into DCs using IL-4 and GM-CSF (Sallusto and
Lanzavecchia, 1994). These DCs have been proposed to resemble
dermal DCs. The addition of transforming growth factor-beta
(TGF-b) to these cultures promotes a Langerhans-like pheno-
type (Geissmann et al., 1998), consistent with the known role of
TGF-b for LDC formation in vivo (Borkowski et al., 1996). In both
instances, differentiation is marked by limited cellular prolifera-
tion and cellular identity is determined by the expression levels of
a panel of markers. Indeed, to date, a single deﬁnitive marker of
DC has not been identiﬁed.
Myeloid DCs (including both interstitial and Langerhans DCs)
can also be generated from bone marrow CD34+ progeni-
tors using GM-CSF and tumor necrosis factor-alpha (TNF-α)
(Caux et al., 1997). These cultures are associated with signiﬁcant
expansion, particularly following the addition of stem cell fac-
tor which acts synergistically with GM-CSF and TNF-α to drive
proliferation. Furthermore, as observed with monocyte-derived
Langerhans cells (Geissmann et al., 1998), the addition of TGF-b
has a profound effect on phenotype promoting the formation of
predominantly Langerhans cultures (Strobl et al., 1997a,b). The
addition of Flt-3L to themixwas subsequently shown to be impor-
tant for successful expansion of CD34+ cells isolated from the
peripheral blood of G-CSF mobilized donors and, to date, has
been a standard technique for generating LCs for studies of HCMV
biology.
VIRAL SUBVERSION OF DC FUNCTION
LYTIC INFECTION OF DCs
Much of our understanding of the effect of HCMV on DCs has
been derived from studies on their lytic infection and has been
reviewed recently (Hertel, 2014) and thus the focus of this review
is on the interaction of latentHCMVwithDCs. Importantly, stud-
ies onHCMVdifferentiation-dependent lytic infection of cell lines
have illustrated that there is a direct correlation between permis-
siveness for lytic infection and virus reactivation and that these
observations are re-capitulated in MoDCs (Gönczöl et al., 1985;
Weinshenker et al., 1988; Lathey and Spector, 1991; Riegler et al.,
2000; Hertel et al., 2003; Reeves et al., 2005b). The evidence that
DCs were permissive for HCMV infection was provided by the
Jahn laboratory using the highly endothelial-tropic virus, TB40/e,
to productively infect MoDCs (Riegler et al., 2000). Infection of
both immature and mature DCs was observed – although, in their
hands, the infection of immature MoDCs appeared to be more
efﬁcient. These observations were then complemented by stud-
ies from the Mocarski laboratory who showed that LDCs were
also susceptible to HCMV infection but, unlike MoDCs, only
after CD40L-induced maturation (Hertel et al., 2003). Subsequent
studies have shown that DCs directly isolated from peripheral
blood are also permissive for infection (Kvale et al., 2006; Reeves
and Sinclair, 2013).
What became clear from such data was that HCMV infection of
DCs resulted in a severe down-regulation of cell surface molecules
which impacted on the normal function of DCs as APCs (Riegler
et al., 2000; Grigoleit et al., 2002; Moutaftsi et al., 2002, 2004; Her-
tel et al., 2003; Lee et al., 2006, 2011; Huang et al., 2012). Although
viral genes encoding immune evasion functions are expressed in
all cell types, the sheer abundance of immune-evasins expressed
by the virus suggests the evolution of an intimate relationship
between HCMV and key immune effector cells – e.g., the DC
lineage. However, it is worth remembering that, despite all these
immune evasion functions encoded by the virus, the immune sys-
tem in healthy individuals still appears to adequately control the
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virus and is able to routinely prevent clinical pathology. Conse-
quently, the functional consequences of this abundance of viral
immune evasion strategies are far from clear during primary
infection or reactivation in vivo. Work on the rhesus model has
illustrated that the US2-11 genes are non-essential for primary
infection of CMV-negative animals (Hansen et al., 2010), whereas
the expression of these genes was crucial for infection in the pres-
ence of pre-existing immune response to CMV (Hansen et al.,
2010). It remains to be determinedwhether the expression of US2-
11 may also be important during reactivation from latency or is
solely required for re-infection of hosts with pre-existing immu-
nity to HCMV. Indeed, the immediate-early kinetics of some of
these transcripts arising from theUS2-11 region (e.g., US3) during
primary lytic infection (Tenney and Colberg-Poley, 1991) could
argue for a potential role in the early stages of HCMV reactiva-
tion, if expression of these RNAs during reactivation exhibited
the same expression kinetics as during primary infection. The
inhibition of antigen presentation, particularly of the immune-
dominant IE72 peptides, may provide a window of opportunity
for the virus to reactivate before the immune system regains
control.
HCMV REACTIVATION IN DCs
As stated above, the permissiveness for both lytic infection and
HCMV reactivation in the myeloid lineage is also closely linked
with the differentiation status of the cell. Given that the initiation
of a lytic infection requires the prodigious activities of both the
IE72 and IE86 proteins, whose expression is driven by the major
immediate-early promoter (MIEP), it has been hypothesized that
differentiation-dependent regulation of the MIEP underpins both
permissiveness for infection of a myeloid cell type as well as
reactivation from latency (Sinclair and Sissons, 1996).
First, in the case of infection of a permissive cell type, there is
a pre-requisite for the virus to overcome intrinsic blocks to viral
IE gene expression and, in most differentiated cell types (includ-
ing DCs), the virus achieves this allowing productive infection
to proceed. In contrast, in a non-permissive cell, the virus can-
not overcome these intrinsic blocks and continued suppression of
the MIEP allows the establishment of a quiescent infection that
can ultimately result in viral latency in, for instance, a monocyte
or CD34+ cell. Alternatively, during the scenario of reactivation,
latent/quiescent genomes transit from a nuclear environment that
does not support MIEP activity to one that does. This reactivation
of IE gene expression – the pivotal ﬁrst step toward complete reac-
tivation of infectious virus – must occur in an absence of other
viral factors or virally induced signaling which likely make a pro-
found contribution to MIEP activity upon the de novo infection
of cells permissive for HCMV.
One simple hypothesis which ﬁts these data is that cellular
differentiation increases the availability of cellular transcription
factors that promote MIEP activity and/or decreases the levels of
cellular factors which suppress MIEP activity – but the evidence
for this in primary cells is limited. That said, we do know that
the transfected MIEP is inherently less active in undifferentiated,
compared to differentiated, myeloid cells (Sinclair et al., 1992)-
which would be consistent with the differentiation dependence of
MIEP activity resulting frompositive/negative transcription factor
binding and availability. However, other data suggest that this lin-
ear hypothesis may represent a too simplistic relationship and a
number of other requirements need to be met to facilitate virus
reactivation at the level of the MIEP.
Our ﬁrst studies on reactivation of HCMV from LCs derived
from CD34+ of healthy seropositive donors were entirely con-
sistent with their concomitant permissiveness for lytic infection;
there was an absolute requirement for maturation (with LPS or
CD40L) after differentiation for HCMV reactivation (Reeves et al.,
2005a,b) and experimental lytic infection to occur (Hertel et al.,
2003). Similarly, more recent work using monocyte-derived LCs
(MoLCs) also shows that maturation of these cells is required
for both HCMV reactivation and their permissiveness for lytic
infection (Huang et al., 2012).
The story regarding reactivation from MoDCs in vitro was less
clear. In our initial studies, the detection of HCMV reactivation
from naturally latent individuals required LPS-induced matura-
tion of the DCs (Reeves et al., 2005b). Thus, although immature
DCs were permissive for HCMV lytic infection (Riegler et al.,
2000) they did not appear to support detectable reactivation.
However, what became evident in subsequent studies was that
immature DCs could support HCMV reactivation if stimulated
with the inﬂammatory cytokine interleukin-6 – circumventing the
need for maturation (Reeves and Compton, 2011). Failure to reac-
tivate in these immature DCs was not due to an intrinsic block to
reactivation but more to a lack of a robust signal to drive the
expression of the IE genes critical for reactivation to occur.
Indeed, some of the very ﬁrst observations of HCMV reac-
tivation in the DC lineage utilized a highly pro-inﬂammatory
cytokine environment to support reactivation (Soderberg-Naucler
et al., 1997; Hahn et al., 1998). DCs themselves are prodigious pro-
ducers of inﬂammatory cytokines, particularly upon stimulation
with bacterial products such as LPS which probably drives the
reactivation observed in vitro using these cell types. Furthermore,
models of HCMV reactivation have usually relied on co-culture
with ﬁbroblasts (Hahn et al., 1998; Goodrum et al., 2002; Reeves
et al., 2005a) which are similarly efﬁcient cytokine producers – and
this includes interleukin-6 (Sundararaj et al., 2009). Interestingly,
treatment of long-term culture of non-adherent experimentally
latentmonocytes inmedia supplementedwith interleukin-6 (IL-6)
has been shown to induceHCMVreactivation (Hargett and Shenk,
2010) and, similarly, the LPS-mediated reactivation of HCMV
from experimentally latent immature DCs has been shown to be
dependent on IL-6 (Reeves and Compton, 2011). Perhaps not
unsurprisingly, then, the addition of IL-6 directly to immature
DCs is known to circumvent the need to induce maturation and,
reciprocally, the ablation of IL-6 signaling in LPS-treated imma-
ture DCs is sufﬁcient to impede virus reactivation (Reeves and
Compton, 2011).
In order to understand the mechanisms controlling HCMV
reactivation it becomes important to deﬁne what is understood
by the repression of the MIEP during latency. For instance, is
the MIEP completely silenced or is the MIEP just signiﬁcantly
repressed to prevent the initiation of the lytic replication cycle? As
such, does inﬂammation just enhance the activity of the MIEP
rather than trigger reactivation? Indeed, the evidence of tran-
scription initiation from “repressed” cellular genes in stem cells
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(Guenther et al., 2007) suggests that sporadic initiation of RNA
Pol II activity at the MIEP may also be expected. Accordingly,
the existence of a virally encoded miRNA species that targets the
major IE transcript (Grey et al., 2007) would be consistent with
a requirement to regulate IE expression post-transcriptionally, at
least during some stage of the viral lifecycle. Since it is unlikely
that such an miRNA would counter the super-abundance of
the IE transcripts during lytic infection, it is possible that such
an RNAi-based mechanism could be important during HCMV
latency (Grey et al., 2005, 2007; Murphy et al., 2008). Indeed,
expression of the UL122 and UL123 transcripts from the MIE
region is unlikely to have a functional impact if they remain
untranslated.
There is good evidence that cellular factors play an important
role in regulating theMIEPduring latency and reactivation in adif-
ferentiation dependent manner (reviewed in Reeves and Sinclair,
2008). Furthermore, more recent data suggest that the establish-
ment and maintenance of HCMV latency may be dictated by
the activity of viral factors. For instance, the exclusion of pp71
from the nuclei in CD34+ cells during the initial stages of infec-
tion (Saffert et al., 2010) combined with the recruitment of the
polycomb repressor complex by the viral lncRNA4.9 transcript
to the MIEP (Rossetto et al., 2013) may contribute to establish-
ment and maintenance of the latent state. Our own work in
primary DCs (Kew et al., 2014), along with studies in cell lines
which show a differentiation-dependency for infection, points
toward an important role for the CREB response elements within
the MIEP for HCMV reactivation (Keller et al., 2007; Yuan et al.,
2009). However, it is of note that around 4000 genes exhibit
CREB occupancy in the human genome (Zhang et al., 2005).
Unsurprisingly, agonists of the cAMP pathway, whilst promoting
CREB phosphorylation, did not necessarily trigger gene expres-
sion from all these loci (Zhang et al., 2005). Critically, the cellular
co-factors available to interact with CREB are likely to dictate
speciﬁc responses. Consequently, it is thus likely that a similar
requirement for co-factor availabilitywill also drive responsiveness
of the MIEP to such signals in multiple cell types. Thus, inte-
grating the role of inﬂammation, cellular signaling, and cellular
differentiation will provide the basis for delineating the mecha-
nisms that govern MIEP regulation during HCMV latency and
reactivation.
DOES HCMV REACTIVATE IN AN IMMUNE-DEFICIENT
ENVIRONMENT?
The observation that HCMV maintains latency and reactivates
in the archetypal control cell of the adaptive immune response
may, at ﬁrst glance, seem like a ﬂawed strategy – virus reactiva-
tion occurs in cells which, themselves, mediate the activation of
a potent arm of the anti-pathogen immune response and which
could be argued to be able to promote highly efﬁcient control of
HCMV infection. Indeed, the known memory inﬂation of T cells
that recognize HCMV in healthy individuals does suggest regular
immune priming events which could be due to regular low-level
reactivation which, for the most part, is asymptomatic.
Alternatively, reactivation in terminally differentiated cells of
the myeloid lineage could be considered analogous to the Trojan
horse model whereby the virus is actually carried and reactivates
in the optimum cell type for the virus to control host immune
responses, thereby permitting efﬁcient viral persistence. Clearly,
the surfeit of immune evasion molecules encoded by the virus
would lend itself enormously to this type of “hijacking” of normal
host immune control mechanisms. In essence, by reactivating in
DCs the virus is positioned to control the bioactivity of a cell type
which is crucial to the control of viral infections.
Whilst reactivationof viral lytic infection in terminally differen-
tiated myeloid cells will almost certainly result in a transcription
program essentially akin to an experimental lytic infection this,
to our knowledge, has not been tested directly. In contrast, in
latently infected cells there is, as yet, no compelling evidence to
suggest that such functions are expressed. One virally encoded
gene with potent immune modulatory effects, however, is known
to be expressed during latent infection, i.e., viral interleukin-10
(vIL10; Jenkins et al., 2008b).
INTERLEUKIN-10
Interleukin-10 (IL-10) is major cellular cytokine with well-
documented, immune-suppressive properties (Opal and Huber,
2000). In normal individuals, IL-10 expression likely represents
the counter-effect to excessive inﬂammation providing a negative
feedback to maintain homeostasis in the immune system rather
than promoting immune-suppression. However, evidence sug-
gests that HCMV harnesses IL-10, both cellular and via virally
encoded IL-10 homologues, to drive an immune-dampening
phenotype that could enhance both lytic and latent infection
(Slobedman et al., 2010; Mason et al., 2012).
Cellular IL-10 (cIL-10) homologues encoded by HCMV (vIL-
10) are known to be expressed in both lytic and latent infection
(Jenkins et al., 2004, 2008a; Cheung et al., 2006). Reviewed exten-
sively elsewhere, a number of studies using the rhesus CMV model
have illustrated that vIL-10 proteins are important for dissemina-
tion of virus upon primary infection (Chang and Barry, 2010)
and, combined with studies of HCMV in vitro, that this could
be due to a functional impact of vIL-10 on MHC class II expres-
sion along with an immune-dampening effect on T-cell responses
to HCMV infected cells (Spencer et al., 2002; Chang et al., 2004;
Raftery et al., 2004; Cheung et al., 2009). Furthermore, there is
evidence that vIL10 expressed during latency may promote a
non-classical differentiated myeloid phenotype (Avdic et al., 2011,
2013). For instance, the expression of the latent form of vIL10
in myeloid progenitors has a dramatic impact on cellular differ-
entiation - in infected monocytes, vIL10 drives monocytes to an
M2c macrophage phenotype which is known to have diminished
immune responses (Avdic et al., 2013). Furthermore, expres-
sion of vIL-10 in granulocyte-macrophage progenitors abrogates
their differentiation to a classical DC phenotype (Avdic et al.,
2011). Thus, both strategies would contribute to successful persis-
tence of the virus in the host by preventing normal recognition
of a latently infected cell by the immune response. Further-
more, in the light of recent work that has studied the role of
patrolling monocytes in the dissemination of MCMV (Daley-
Bauer et al., 2014) vIL-10 may play other roles. For instance,
patrolling monocytes can generate anti-inﬂammatory signature
in response to pathogens which is exempliﬁed by IL-10 pro-
duction. Therefore, it is possible that the immune-privileged
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phenotype associated with these monocytes could also involve
IL-10 and in the context of CMV infection, enhance viral
dissemination.
cIL-10 also exerts a number of effects on APCs and on the
T cells that interact with them. For instance, addition of cIL-
10 to APCs promotes signiﬁcant down-regulation of MHC class
II surface expression which impacts on CD4 T-cell responses
(Koppelman et al., 1997). Furthermore, cIL-10 also imparts a
functional effect on T cells – driving the recruitment of immune-
suppressive cells on an cIL-10 gradient and acting to suppress the
function of classical effector CD 4 T cells (Groux et al., 1996).
Indeed, it is hypothesized that the induction of cIL-10 (with TGF-
b) by latently HCMV-infected CD34+ cells contributes to the
generation of an immune-suppressive environment in the proxim-
ity of latently infected cells, thus protecting them from elimination
by the host immune response (Mason et al., 2012).
US GENES AND VIRAL miRNAs
Human cytomegalovirus encodes a number of gene products
that are important for regulating both MHC class I- and class
II-mediated antigen presentation. These proteins (expressed from
genes encoded by the US2-11 region of HCMV) target multiple
aspects of the antigen presentation pathway in an attempt to ren-
der the infected cell invisible to the immune response (Powers
et al., 2008). Expressed throughout lytic infection, these viral gene
products target MHC surface expression, antigen processing, and
loading aswell as thedelivery of peptide-loadedMHCmolecules to
the cell surface. The evolution of multiple immune evasion genes
suggests a strong selective pressure on the virus to evolve robust
counter-measures to a sophisticated host immune response. As
expected, these genes are non-essential in vitro and studies with
rhesus CMV (RhCMV) have also suggested they are dispensable
for primary infection also (Hansen et al., 2010). Instead, the US
gene products (particularly, 2, 3, 6, and 11) were required for
super-infection of rhesus macaques with RhCMV (Hansen et al.,
2010). Thus, it is hypothesized that the US 2-11 genes are required
for re-infection of a host with a pre-existing immunity to CMV.
The reason for this is unclear but, potentially, the capacity of
the virus to super-infect individuals with pre-existing anti-viral
immunity could increase the potential for genetic recombina-
tion between multiple strains of HCMV which could impact on
virus persistence in vivo. Clearly, the expression of these potent
immune-evasins inDCs reactivatingHCMV likely plays an impor-
tant role in efﬁciency of virus reactivation to allow horizontal and
vertical transmission as well as, possibly, the maintenance of the
latent reservoir.
The expression of such an effective repertoire of immune eva-
sion molecules during lytic infection begs the question as to why
HCMV also encodes at least one miRNA which is involved in
de-regulating antigen processing and presentation. This virally
encoded miRNA,miRNA US4-1, has been shown to target ERAP –
a key cellular protein for the processing of antigens for MHC pre-
sentation (Kim et al., 2011). However, why additional mechanisms
involving miRNAs might be required to target antigen presenta-
tion during lytic infection when such cellular functions are already
extensively targeted by key viral immune evasion proteins are
intriguing. It is possible that miRUS4-1 has additional functions
or that that it provides a “belt and braces” approach to ensure
efﬁcient regulation of antigen presentation by the virus. Similarly,
whether the real function lies during latency (where many viral
proteins are not expressed) or in cell types other than ﬁbroblasts
(where viral gene expression may be less efﬁcient) remains to be
determined.
INFLAMMATION AND HCMV
The contribution of the cellular environment to HCMV reacti-
vation has been studied intensely using models of myeloid cell
differentiation. An important aspect that deﬁnes the cellular
environment is the action of the extra-cellular milieu. Indeed,
inﬂammation and HCMV viraemia and disease in a number
of patient populations are closely linked (Humar et al., 1999;
Blankenberg et al., 2001). Consistent with a role for inﬂam-
mation, a number of studies of HCMV reactivation have sug-
gested that key inﬂammatory cytokines such as TNF-α, IL-6,
and interferon-y could be important factors for reactivation
(Humar et al., 1999). Hypothetically, HCMV disease may be
linked to the inﬂammation associated with allograft rejection
and GvHD. HCMV reactivation and disease have been sug-
gested to be the risk factors in sepsis patients (Heininger et al.,
2001) and indeed LPS is a prodigious stimulator of cytokine
production in multiple cell types. In contrast, the use of anti-
inﬂammatory treatments (which may be predicted to reduce
HCMV reactivation through diminished inﬂammation), such
as TNF antagonists like ENTERCERPT, to treat auto-immune
diseases, has been associated with increased herpes virus reac-
tivation (Kim and Solomon, 2010). Consequently, attempts to
dampen the auto-immune response with such anti-inﬂammatory
drugs are likely to impact on the normal regulation of HCMV
reactivation also. Essentially, reducing inﬂammation may dimin-
ish the level of HCMV reactivation observed at a molecular
level. However, reduced immune activity associated with anti-
inﬂammatory treatments may have a negative impact on the
level of immune control normally exerted on HCMV in healthy
individuals.
One in vitro model for HCMV reactivation from monocytes
speciﬁcally uses IL-6-induced signaling via the ERK-MAPK path-
way (Reeves and Compton, 2011). Clearly, many cytokines could
potentially activate this signaling pathway – so an obvious ques-
tion is whether IL-6, itself, is important for HCMV reactivation
in vivo. Unfortunately, the limited clinical data are not equivocal.
Aggressive HCMV disease is known to be associated with elevated
IL-6 serum levels (Humar et al., 1999; Blankenberg et al., 2001).
However, such studies were not designed to distinguish between
a potential role for inﬂammation in virus reactivation and the
clinical outcomes of induction of inﬂammation during viraemia.
It is known that systemic IL-6 production is important for over-
coming immune-suppression, elicited by T regulatory cells, by
driving a T effector cell function (Wan et al., 2007) – an event
that has been speculated to be particularly important in graft
rejection (Liang et al., 2007). Consequently, why the induction of
HCMV reactivation in response to IL-6 has evolved is unclear – as
it would result in reactivation in the presence of a strong anti-viral
immune response. Intriguingly though, IL-6 has unique effects
on DCs in vitro. In essence, treatment of DCs with IL-6 results
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in the generation of a DC cell type that remains functionally
immature compared with LPS or CD40L activated DCs (Hegde
et al., 2004). This effect of IL-6 on DCs potentially generates a
cell type that supports HCMV reactivation but, at the same time,
is not fully capable of acting most effectively as an antigen pre-
senting cell. Taken together, the fact that HCMV encoded vIL10
is also immune-suppressive (Spencer et al., 2002; Jenkins et al.,
2008b) and latent infection of CD34+ cells results in induction
of immune-suppressive cIL-10 (Mason et al., 2012) suggests that
HCMV beneﬁts from manipulating the DC cell to an intermediate
phenotype which is functionally just short of mature classical DCs
or macrophages (Avdic et al., 2013).
Whether IL-6 is a “master cytokine” in vivo for HCMV reac-
tivation is unclear. Human cytomegalovirus reactivation from
monocytes, as a result of allogeneic T-cell stimulation (Soderberg-
Naucler et al., 1997), appeared to result from the extensive
induction of inﬂammatory cytokines, one of which was IL-6
(Soderberg-Naucler et al., 2001). However, high levels of many
other cytokines such as TNF-α and interferon gamma were also
detected – and antibody neutralization of both of these abrogated
virus reactivation (Soderberg-Naucler et al., 2001). Indeed, it has
been hypothesized that the coincidence of HCMV reactivation
with GvHD (which is also driven by allogeneic T-cell activation) is
mimicked in this system and that, in vivo, HCMV might respond
to the excessive inﬂammation associated with GvHD. Of course,
viral reactivation and re-entry into the lytic cycle will likely result
in inﬂammation, in itself, and thus a destructive positive feedback
loop could exacerbate GvHD in these CMV-infected individuals.
Ultimately, the “litmus test”would be to determine whether using
neutralizing antibodies against IL-6 reduces HCMV reactivation
in vivo.
TNF-α has also long term been proposed to be important for
CMV reactivation in vitro and in vivo (Prösch et al., 1999, 2002;
Hummel and Abecassis, 2002; Cook, 2007) and, consistent with
this, it is well known that the viral MIEP responds to NF-kB which
is a major downstream effector molecule of the TNF-α signaling
cascade (Cherrington andMocarski,1989; Sambucetti et al., 1989).
Indeed, TNF-α has been used to reactivate HCMV in a number
of cell line models as well as reactivate MCMV in murine models
of virus reactivation (Hummel and Abecassis, 2002; Prösch et al.,
2002; O’Connor and Murphy, 2012). As such, TNF-α antagonists
have been proposed as potential measures to control HCMV reac-
tivation in vivo but, as of yet, no unequivocal evidence has been
presented to conﬁrm this. Indirect support for a role for TNF-α
in HCMV pathogenesis is suggested by the known modulation
of tumor necrosis factor receptor one (TNFRI) expression on the
surface of infected cells by HCMV infection. For instance, both
clinical and laboratory isolates of HCMV down-regulate TNFRI
early during lytic infection (Baillie et al., 2003; Le et al., 2011;
Montag et al., 2011). However, recently, the UL138 gene prod-
uct encoded by HCMV in its ULb’ region has also been shown
to up-regulate TNFR1 cell surface expression (Le et al., 2011;
Montag et al., 2011) – this, perhaps, points to a need for the virus
to modulate this important signaling cascade differentially during
the course of lytic infection. Importantly, UL138 is also known to
be expressed during latent infection (Goodrum et al., 2007) sug-
gesting that HCMV may render cells more responsive to TNFRI
and, thus, potentially prime cells for reactivation. However, formal
proof of this in the context of latent viral infection remains to be
shown.
Indeed, when we begin to consider HCMV reactivation in the
context of myeloid cell differentiation and inﬂammation, a num-
ber of important questions arise. The differentiation-dependent
model of latency predicts that, in early progenitor cells, the latent
HCMV genome is relatively unresponsive to stimuli that would
normally be expected to activate the MIEP. Clearly, cellular dif-
ferentiation, per se, triggers HCMV reactivation in a number of
models – an event that is exacerbated by inﬂammation. How-
ever, in vitro, cytokine stimulation forces the differentiation of
myeloid cells down speciﬁc lineages which may not fully reﬂect
events in vivo. For instance, monocytes isolated from HCMV
viraemic patients display a defect in a GM-CSF paracrine signaling
which, ultimately, could impair their normal differentiation and
immune function (Carlier et al., 2011). Of course, viraemia rep-
resents a speciﬁc condition but it remains to be seen if HCMV
reactivation exerts any effect on the normal differentiation of
myeloid cells in healthy individuals. It is revealing that the effects
on GM-CSF paracrine signaling were mediated by IL-6 (Carlier
et al., 2011) and IL-6 has been shown to trigger higher levels
of HCMV reactivation from monocytes in long-term culture
(Hargett and Shenk, 2010) and differentiating DCs (Reeves and
Compton, 2011; Huang et al., 2012). It is tempting to speculate
that HCMV modulates the cellular microenvironment to pro-
mote HCMV reactivation which, in healthy individuals, could
contribute to persistence of the virus. However, in the con-
text of immune-compromised individuals this becomes a source
for uncontrolled virus replication and dissemination resulting
in severe morbidity. HCMV clearly expresses a bioactive secre-
tome during latency in vitro (Mason et al., 2012) which would be
augmented by the activity of virally encoded functions such as
vIL-10 (Slobedman et al., 2010). Taken together, these activities
may also be responsible for modulating the function of differen-
tiating monocytes and myeloid precursors to a phenotype that is
relatively immune-suppressive (Hargett and Shenk, 2010; Avdic
et al., 2011, 2013). Thus, while the model predicts that cellular dif-
ferentiation is important for HCMV reactivation, it is becoming
clear that the virus could hijack speciﬁc pathways to modulate cel-
lular functions to support reactivation in a cell type that is not a
classical DC.
FINAL COMMENTS
Human cytomegalovirus exhibits a very close relationshipwith the
cells of the myeloid lineage – and particularly macrophages and
DCs. DCs likely represent an important cell type for the resolution
of primary infection and also for the control of reactivation. The
HCMV genome is dominated by gene products that are impor-
tant for immune-modulation including a signiﬁcant number of
genes that target components of the adaptive immune response.
A key role of DCs is to respond to pathogens to elicit an effective
immune response via the activation of T lymphocytes. Part of the
response of DCs involves signiﬁcant activation of key inﬂamma-
tory cytokines and chemokines that contribute to the successful
resolution of the infection. Interestingly, the viral MIEP exhibits
a number of similarities with the promoters of genes encoding
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these key inﬂammatory mediators, suggesting that the viral MIEP
behaves as a cryptic inﬂammatory promoter which responds to
the same regulatory inﬂammatory signals. In itself, this may still
prove to be ineffective for the virus in the face of a normal and
robust immune response. However, when reactivation is consid-
ered in the context of the range of other strategies HCMV employs
to diminish the strength of the immune response during latency
and reactivation, reactivation in immunologically “impaired”DCs
could provide the ideal spring-board for viral reactivation, dis-
semination and, possibly, transmission. In the setting of, often
iatrogenic, host immune-suppression this delicate balance is dra-
matically tipped toward the virus where it results in the serous
morbidity often associated with this opportunistic pathogen. The
general belief thatmyeloid cell differentiation alongwith concomi-
tant inﬂammatory signaling is important for triggering HCMV
reactivation in the myeloid lineage is supported by a wealth of
data However, as we begin to understand the increasingly complex
interaction of HCMVwith the immune system, it will become fun-
damentally important to dissect the mechanisms HCMV employs
to usurp the normal biology of myeloid cells such as DCs to
facilitate viral reactivation and the successful persistence of this
opportunistic pathogen.
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